AureoGen Biosciences

AureoGen's therapeutic focus is on antibiotics, and the company’s mission is to leverage state-of-the-art chemical and genetic engineering methods to generate new drug candidates from existing cyclic peptide templates. AureoGen is utilizing the latest advances in medicinal chemistry to develop novel approaches for the efficient and cost-effective modification, optimization, and production of cyclic peptide compounds. AureoGen’s chemistry allows for the direct introduction of numerous modifications (to cyclic peptides) without the need for multiple synthetic steps, breakdown of the core ring structure, and resynthesis of most of the molecule, which are characteristic of older methods. Similarly, advancements in biology and genetics have yielded tools and knowledge that enable efficient structural modifications of their synthesis in organisms through the genetic engineering of non-ribosomal peptide synthetase (NRPS) complexes. Thus, by employing cutting-edge chemical and genetic engineering methods, AureoGen is producing new cyclic peptide-based drug candidates that are novel chemical entities (NCEs) and possess the pharmacological properties required to be developed into useful therapeutic agents.